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he overexpression of members of the ErbB tyrosine
kinase receptor family has been associated with
cancer progression. We demonstrate that focal ad-
hesion kinase (FAK) is essential for oncogenic transfor-
mation and cell invasion that is induced by ErbB-2 and -3
receptor signaling. ErbB-2/3 overexpression in FAK-deﬁ-
cient cells fails to promote cell transformation and rescue
chemotaxis deﬁciency. Restoration of FAK rescues both
oncogenic transformation and invasion that is induced by
ErbB-2/3 in vitro and in vivo. In contrast, the inhibition of
FAK in FAK-proﬁcient invasive cancer cells prevented cell
invasion and metastasis formation. The activation of
T
 
ErbB-2/3 regulates FAK phosphorylation at Tyr-397, -861,
and -925. ErbB-induced oncogenic transformation corre-
lates with the ability of FAK to restore ErbB-2/3–induced
mitogen-activated protein kinase (MAPK) activation; the
inhibition of MAPK prevented oncogenic transformation.
In contrast, the inhibition of Src but not MAPK prevented
ErbB–FAK-induced chemotaxis. In migratory cells, acti-
vated ErbB-2/3 receptors colocalize with activated FAK
at cell protrusions. This colocalization requires intact FAK.
In summary, distinct FAK signaling has an essential func-
tion in ErbB-induced oncogenesis and invasiveness.
 
Introduction
 
The ErbB family of tyrosine kinase receptors includes EGF re-
ceptor (ErbB-1), ErbB-2, -3, and -4. The overexpression of
specific members of the ErbB tyrosine kinase receptor family,
particularly ErbB-2 (Her-2), has been associated with poor prog-
nosis and invasiveness in human cancer (Slamon et al., 1987) as
well as ErbB-2/Neu transgenic mice (Guy et al., 1992).
ErbB receptor ligands are divided into three categories:
(1) those that bind EGF receptor alone, such as EGF; (2) those
that bind to ErbB-3 or -4, which are represented by heregulins
(HRGs); and (3) those that bind to ErbB-4 or EGF receptor,
such as betacellulin. Ligand binding to the receptor induces
receptor autophosphorylation, homodimerization, and hetero-
dimerization, with ErbB-2 being the preferred partner for het-
erodimerization (Pinkas-Kramarski et al., 1996). The biological
activity of ErbB receptors is attributed primarily to cooperative
signaling via ErbB heterodimers, whereas homodimers are
weakly active or are devoid of kinase activity (e.g., ErbB-3;
Guy et al., 1994). Interestingly, the cooverexpression of multi-
ple ErbB receptors within the same tissue and cell is common
in invasive cancers from humans (Lemoine et al., 1992; Ali-
mandi et al., 1995; Naidu et al., 1998; Xia et al., 1999) and
transgenic mice (Siegel et al., 1999).
The mechanisms by which ErbB overexpression con-
tributes to tumor cell invasion are not fully understood. One
important early event that has been implicated as a potential
molecular switch for cell migration induced by growth factors
is the activation of the nonreceptor FAK. FAK is a major pro-
tein of the focal adhesion complex that plays a key role in cell
migration and matrix survival signals (Ilic et al., 1995; Frisch
et al., 1996; Sieg et al., 1999). FAK is activated by a number of
growth factors, including the ErbB ligands EGF (Sieg et al.,
2000; Lu et al., 2001) and HRG (Vadlamudi et al., 2002), and
follows integrin clustering in response to components of the
extracellular cell matrix.
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In this study, we dissected the function of FAK in onco-
genic transformation versus cell invasion that is induced by the
cooperation between ErbB-2 and -3 tyrosine kinase receptors
in the context of receptor overexpression. These receptors were
overexpressed as single and paired combinations using FAK
 
 
 
/
 
 
 
cells, FAK
 
 
 
/
 
 
 
 cells, FAK
 
 
 
/
 
 
 
 in which FAK was reconstituted,
and invasive human breast cancer cells in which FAK was in-
hibited by short inhibitory RNA (siRNA). We demonstrate that
ErbB-induced oncogenic transformation and cell invasion are
dependent on FAK. ErbB-2/3–induced oncogenic transforma-
tion is FAK–Src–MAPK dependent, whereas ErbB-2/3–induced
cell invasion is FAK–Src dependent.
 
Results
 
Expression and activation of ErbB 
receptors in FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells
 
Both FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells express very low levels of
ErbB-1, but -2, -3, and -4 were not detected by Western blot
analysis (Fig. 1 A), making this model very appropriate to ad-
dress the biological impact of ErbB overexpression. We fo-
cused on ErbB-2 and -3 overexpression based on preliminary
data showing that FAK-proficient cells cooverexpressing the
ErbB-2 and -3 combination were the most invasive in vivo and
on the Boyden chamber assay compared with cells overex-
pressing the other ErbB receptor combinations (Fig. S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200504124/
DC1). FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells were stably transduced with a
retrovirus that expresses ErbB-2 or -3 receptor and enhanced
GFP. Receptor expression in cells that were transduced with
control retroviral particles or particles encoding ErbB-2 and/or
-3 receptors was confirmed by Western blot assay (Fig. 1 A)
and immunofluorescence analysis (Fig. 1 B).
ErbB tyrosine phosphorylation after 10 min of cell stimu-
lation with 20 ng/ml EGF or HRG was measured by receptor
immunoprecipitation and Western blot analysis (Fig. 1 C).
Constitutive receptor autophosphorylation in the absence of
ligand was seen in both FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells overexpress-
ing ErbB-2 receptor alone or in combination with ErbB-3,
which is consistent with the property of ErbB-2 to undergo
constitutive autophosphorylation in the absence of ligand acti-
vation (Pinkas-Kramarski et al., 1996). In contrast, EGF or
HRG induced no or a slight increase in ErbB-3 phosphoryla-
tion in cells overexpressing ErbB-3 alone (Fig. 1 C). ErbB-3
has an impaired kinase activity (Guy et al., 1994), and the
slight increase in phosphorylation upon stimulation with EGF
or HRG (Fig. 1 C) is likely attributed to transphosphorylation
by endogenous ErbB-1 that is present in these cells (Fig. 1 A).
Coexpression of ErbB-2 with -3 in FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells
resulted in robust ErbB phosphorylation, particularly after
stimulation with the ErbB-3 ligand HRG as a result of receptor
heterodimerization and transphosphorylation.
 
FAK is required for ErbB-induced 
oncogenic transformation
 
Parental FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 cells exhibit no apparent mor-
phological changes that reflect cell transformation, and they
lack the ability to grow on soft agar and form tumors in immu-
nocompromised mice
 
 
 
(see Fig. 3). Neither control FAK
 
 
 
/
 
 
 
 nor
FAK
 
 
 
/
 
 
 
 cells expressing empty retroviral particles that were
used to express ErbB receptors formed colonies in soft agar. In
contrast, FAK
 
 
 
/
 
 
 
-2 and -2/3 cells, but not FAK
 
 
 
/
 
 
 
-3 or any
FAK
 
 
 
/
 
 
 
–ErbB-expressing cells, were able to grow on soft agar
and form large foci; the coexpression of ErbB-2 with -3 re-
Figure 1. Overexpression of ErbB-2, -3, and -2/3 in FAK
 /  and FAK
 / 
cells. (A) Cells expressing control retroviral particles or ErbB receptors
were subjected to Western blotting using specific ErbB antibodies as de-
scribed in Materials and methods. (B) Cells were fixed and double stained
for ErbB-2 and -3 using specific antibodies and were examined by immuno-
fluorescence microscopy. Note that FAK
 /  and FAK
 /  control cells do
not express any ErbB-2 or -3 receptors, whereas FAK
 / -2/3 and FAK
 / -
2/3 exhibited strong labeling for both receptors. Bar, 40  m. (C) Cells
were serum starved for 24 h and kept unstimulated (control, C) or were
stimulated with 20 ng/ml EGF (E) or HRG (H) for 10 min. Cell lysates
were immunoprecipitated with anti-ErbB, and the blots were probed using
antiphosphotyrosine antibody and reprobed with the corresponding ErbB-
specific antibody. 
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sulted in strong oncogenic transformation compared with
ErbB-2 alone (Fig. 2 B and Fig. S2 A, available at http://
www.jcb.org/cgi/content/full/jcb.200504124/DC1).
To prove that FAK is required for ErbB-induced cell
transformation, we reconstituted FAK in FAK
 
 
 
/
 
 
 
 cells ex-
pressing ErbB-2 and -3 combinations (Fig. 2 A). Interest-
ingly, the restoration of FAK in FAK
 
 
 
/
 
 
 
-2/3 and -2 rescued
the ability of ErbB to induce anchorage-independent growth
on soft agar but did not in control FAK
 
 
 
/
 
 
 
 cells or FAK
 
 
 
/
 
 
 
cells overexpressing the kinase-deficient receptor ErbB-3
(Fig. 2 B and Fig. S2 A).
 
FAK is required for ErbB-induced cell 
chemotaxis
 
Upon EGF or HRG stimulation, no to very low invasive activ-
ity was detected in control cells and in cells overexpressing the
kinase-deficient ErbB-3, whereas FAK
 
 
 
/
 
 
 
-2 and -2/3 cells ex-
hibited an increase in invasion upon HRG stimulation, with
cells overexpressing ErbB-2/3 being the most chemotactic
(Fig. 2 C and Fig. S2 B). FAK
 
 
 
/
 
 
 
 cells expressing control retro-
viral particles or any of the ErbB-2 and -3 combinations were
weakly invasive, whereas FAK
 
 
 
/
 
 
 
-2 and -2/3 in which wild-
type FAK was reconstituted (FAK
 
 
 
/
 
 
 
-2–FAK and FAK
 
 
 
/
 
 
 
-2/3–
FAK, respectively) exhibited an increase in invasion upon
HRG stimulation. This rescue was not observed in control
FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
-3 stably expressing wild-type FAK (Fig.
2 D and Fig. S2 B).
 
ErbB-induced tumorigenicity and 
metastasis formation are dependent 
on FAK
 
To investigate the impact of FAK on ErbB-induced in vivo
tumorigenicity, control and ErbB-transduced (ErbB-2, -3, and
-2/3) cells were transplanted subcutaneously into Scid mice.
Neither FAK
 
 
 
/
 
 
 
 nor FAK
 
 
 
/
 
 
 
cells that were transduced with
control retroviral particles or ErbB-3 receptor formed tumors
after 
 
 
 
35 d (Fig. 3 A). The overexpression of ErbB-2 and
-2/3 in FAK
 
 
 
/
 
 
 
 cells induced aggressive tumor growth within
20 d, with ErbB-2/3 cells being the most aggressive compared
with ErbB-2 (P 
 
  
 
0.05; tumors reached a size of 
 
 
 
1.25 cm
 
3
 
 in
 
 
 
14 d for FAK
 
 
 
/
 
 
 
-2/3 vs. 
 
 
 
18 d for FAK
 
 
 
/
 
 
 
-2 cells). In con-
trast, in FAK
 
 
 
/
 
 
 
 cells, tumor sizes were 
 
 
 
0.5 cm
 
3
 
 for both
ErbB-2 and -2/3 (the maximal size was 
 
 
 
0.5 cm
 
3
 
 after 40 d,
but most tumors regressed or became necrotic thereafter). This
pattern of tumor growth was confirmed in three independent
experiments using different cell stocks and with 
 
n
 
 
 
 
 
 8 mice per
condition for each experiment.
To further demonstrate that differences in tumor growth
between FAK
 
 
 
/
 
 
 
–ErbB and FAK
 
 
 
/
 
 
 
–ErbB is directly related to
FAK, we examined the impact of FAK reconstitution on tu-
morigenesis of FAK
 
 
 
/
 
 
 
-2/3 cells, focusing on ErbB-2/3 as the
most aggressive in FAK
 
 
 
/
 
 
 
. As shown in Fig. 3 B, the expres-
sion of wild-type FAK in FAK
 
 
 
/
 
 
 
-2/3 clearly restored tumor
formation. In contrast, the restoration of FAK in control FAK
 
 
 
/
 
 
 
did not induce tumor formation. In FAK
 
 
 
/
 
 
 
-2/3–FAK, we
noted a clear delay for the tumors to reach exponential tumor
growth phase compared with FAK
 
 
 
/
 
 
 
-2/3. This difference can-
not be attributed to a loss of ErbB receptor expression in vivo
because we confirmed by immunohistochemistry that ErbB re-
ceptors were highly expressed in tumor sections collected at
the time of killing or in primary cells established from these tu-
mors (unpublished data).
To determine whether the impact of FAK on ErbB-induced
tumorigenicity paralleled metastasis formation, we examined
the capacity of ErbB-overexpressing cells to form lung me-
tastases after intravenous cell administration, which mimics
a late stage of the metastatic process (extravasation). Both
FAK
 
 
 
/
 
 
 
 and FAK
 
 
 
/
 
 
 
 control cells that were transduced with
Figure 2. FAK is essential for ErbB-induced
oncogenic transformation and chemotaxis.
(A) Western blot analysis to show FAK expres-
sion status in FAK
 /  cells expressing various
ErbB receptor combinations and their matched
cells in which wild-type FAK was reconstituted
by stable transfection, as indicated in Materials
and methods. FAK
 / –ErbB-2/3 cells are in-
cluded as a control. (B) Oncogenic property of
FAK
 / - and FAK
 / -expressing ErbB-2/3 re-
ceptors. Cells were cultured in medium con-
taining soft agarose, and colony formation
was determined 4 wk later by counting the
number of cell foci of  20  m in diameter (Fig.
S2 A, available at http://www.jcb.org/cgi/
content/full/jcb.200504124/DC1). Each bar
on the graph represents the mean number of
colonies per well from three independent ex-
periments   SD. (C and D) ErbB-induced cell
invasion in FAK
 /  (C), FAK
 / , and FAK
 / 
cells in which FAK was restored (D). FAK
 / ,
FAK
 / , and FAK
 / -reconstituted cells express-
ing ErbB receptors were cultured in the upper
chamber, whereas EGF or HRG was used as a
chemoattractant in the lower chamber. Each
bar of the graphs represents the mean   SD
(error bars) of invading cells from three inde-
pendent experiments. C, control.JCB • VOLUME 171 • NUMBER 3 • 2005 508
empty retroviral particles or FAK
 /  and FAK
 /  overexpress-
ing ErbB-3 induced no or very few macroscopic lung nodules.
The overexpression of ErbB-2 or -2/3 increased the incidence
of lung metastases. However, the ErbB-2/3 combination was
much more potent in inducing macroscopic lung metastases in
FAK
 /  cells compared with cells overexpressing ErbB-2 re-
ceptor alone or FAK
 /  overexpressing ErbB-2 or -2/3 receptors
(P   0.05; Fig. 3 C).
To further demonstrate that the reduced number of lung
metastases in FAK
 / -2/3 compared with FAK
 / -2/3 is directly
related to FAK, we examined the impact of FAK on lung me-
tastasis formation in FAK
 / -2/3 cells in which wild-type FAK
was restored. As shown in Fig. 3 D, the restoration of FAK in
FAK
 / -2/3 cells partially rescued the deficiency in invasion
(P     0.05 when comparing FAK
 / -2/3 with FAK
 / -2/3–
FAK). This partial rescue may be contributed by lower levels
of FAK expression in FAK
 / -2/3 compared with endogenous
FAK in FAK
 /  cells (Fig. 2 A).
ErbB-induced oncogenic transformation 
and invasion are mediated via distinct 
FAK signaling
To dissect the FAK-dependent signaling involved in ErbB-
induced oncogenesis and invasion, we examined the impact of
ErbB on FAK phosphorylation and its interaction with down-
stream signaling partners. FAK phosphorylation occurs at sev-
eral tyrosine sites, including Tyr-397, -861, and -925; these
sites are selectively regulated after ErbB activation (Sieg et
al., 2000; Lu et al., 2001; Vadlamudi et al., 2002, 2003). In
FAK
 /  control cells, the stimulation of ErbB by EGF resulted
in a small increase in the level of FAK phosphorylation over
time (Fig. 4 A, top left), whereas HRG had no effect on basal
FAK phosphorylation (not depicted). The stimulation of cells
overexpressing ErbB-2 with EGF increased total FAK phos-
phorylation as well as phosphorylation at Tyr-397, -861, and
-925. This increase is likely a result of ErbB-2 transactivation
by the low endogenous ErbB-1 present in these cells. FAK ac-
Figure 3. FAK is required for ErbB-induced
tumor progression and tumor invasion in
vivo, whereas the restoration of FAK in FAK
 / 
cells rescued the deficiency in tumor invasion.
(A) Tumor growth kinetics after subcutaneous
implantation of cells into the flank of Scid
mice. (B) Tumor growth kinetics after subcuta-
neous implantation of FAK
 / -2/3 and
FAK
 / -2/3–reconstituted cells (FAK
 / -2/3–
FAK); FAK
 / -2/3 cells were used as positive
controls. Tumor growth was monitored over
time as indicated in Materials and methods.
Each point represents the mean of five to
eight mice   SEM. (C) Quantification of lung
surface metastases induced by intravenous
cell administration. (a) Mean surface lung
metastases (n   8–10)   SEM. (b) Represen-
tative lungs from mice inoculated with FAK
 / 
and FAK
 /  control cells (expressing empty
retroviral particles) and cells overexpressing
ErbB-2, -3, or -2/3 receptors. (D) Mean lung
metastases (n    8)    SEM (error bars) in-
duced by FAK
 / -2/3 or FAK-reconstituted
FAK
 / -2/3 (FAK
 / -2/3–FAK). FAK
 / -2/3
cells were used as positive controls. FAK IS ESSENTIAL FOR ERBB ONCOGENESIS • BENLIMAME ET AL. 509
tivation was weak in cells overexpressing kinase-deficient
ErbB-3 that was stimulated with HRG (Fig. 4 A). In cells
overexpressing ErbB-2 and -2/3, a clear increase in total FAK
phosphorylation was seen, which was associated with the in-
creased phosphorylation of Tyr-397, -861, and -925; the most
pronounced increase was seen on Tyr-861 and -925 phosphor-
ylation sites (Fig. 4 A).
ErbB receptors are coupled to several signaling mole-
cules that are also recruited by FAK. These include the
MAPK and Src kinases. We used inhibitors for these kinases
to delineate the signaling events that are associated with
ErbB–FAK-dependent oncogenic transformation versus cell
invasion. As shown in Fig. 4 B, MAPK/extracellular regu-
lated kinase (ERK) phosphorylation is strongly induced after
5 min of stimulation with HRG in FAK
 / -2/3 cells compared
with control FAK
 /  and FAK
 / -2/3 cells. Interestingly, the
reconstitution of FAK in FAK
 / -2/3 cells restored ERK
phosphorylation to approximately the same levels seen in
FAK
 / -2/3 cells. In both FAK-proficient and FAK-recon-
stituted cells, inhibition of the dual-specificity protein ki-
nase Mek1/2 by UO126 efficiently prevented ErbB-induced
MAPK activation (Fig. 4 B, bottom). In FAK
 / -2/3 cells,
immunoprecipitation assay and immunostaining revealed that
the activation of FAK phosphorylation at Tyr-861 and -925
by HRG was inhibited by the Src inhibitor PP2 (Fig. 4 C) but
not by UO126 (not depicted).
We next addressed the impact of MAPK and Src inhibi-
tion on ErbB-induced cell transformation versus cell inva-
sion. As shown in Fig. 4 D, MAPK inhibition by UO126 or
Mek1 dominant mutants prevented ErbB-induced anchorage-
independent growth in soft agar in FAK
 / -2/3 cells and
FAK-reconstituted FAK
 / -2/3 cells. In contrast, only PP2 or
Src dominant mutants prevented ErbB-2/3–induced chemo-
taxis (Fig. 4 E).
Figure 4. ErbB-induced oncogenic transfor-
mation and invasion are mediated via distinct
FAK signaling. (A) Differential regulation of
FAK phosphorylation by ErbB-2 and -3 recep-
tors. Serum-starved cells were stimulated with
20 ng/ml EGF (control cells) or HRG (ErbB-2,
-3, and -2/3–overexpressing cells) for the indi-
cated times. Proteins were immunoprecipi-
tated with anti-FAK and probed with an-
tiphosphotyrosine antibody, antiphospho-FAK
antibodies specific to different residues, and
anti-FAK antibody. (B) Differential regulation
of MAPK phosphorylation by ErbB-2 and -3.
Cell lysates from HRG-stimulated adherent
cells were blotted with P-MAPK and reprobed
with MAPK antibody as indicated in Materials
and methods. The figure shows an increase in
P-MAPK after 5 min of stimulation with HRG
in FAK
 / -2/3 cells and FAK-reconstituted
FAK
 / -2/3 cells compared with control cells.
Exposure to UO126 strongly inhibited P-MAPK
in FAK-proficient cells. (C) Inhibition of Src re-
duced HRG-induced FAK phosphorylation at
Tyr-861 and -925. FAK
 / -2/3 cells were se-
rum starved for 24 h and pretreated with PP2
at 100 nM for 60 min followed by treatment
with 20 ng/ml HRG for 30 min. (a) Whole
cell lysates were immunoprecipitated with anti-
FAK and probed with antiphosphotyrosine anti-
body. Membranes were subsequently reprobed
with antiphospho-FAK antibodies specific to dif-
ferent residues and total FAK. (b) FAK
 / -2/3
cells were coimmunostained for ErbB-2 and
the indicated phospho-FAK in the absence or
presence of PP2. Bar, 40  m. (D) Inhibition of
colony formation on agar by Src and MAPK
inhibition. Cells were cultured in medium con-
taining soft agarose either in the absence and
presence of PP2 or UO126 or were transfected
with dominant mutants for MEK1 or Src. Col-
ony formation was determined 4 wk later by
counting the number of cell foci. (E) Inhibition
of cell invasion by Src but not MAPK inhibition.
Cells were cultured in the upper chamber of the
Boyden chamber in the absence and presence
of PP2 or UO126 or after being transfected
with dominant mutants for MEK1 or Src. HRG
was used as a chemoattractant in the lower
chamber. Each bar of the graphs represents the
mean   SD (error bars) of invading cells from
three independent experiments.JCB • VOLUME 171 • NUMBER 3 • 2005 510
FAK is required for ErbB-2 localization 
at the cell protrusion
To further understand the impact of ErbB–FAK interaction on
the formation of focal adhesions in migratory cells, we first
used the scratch-wound assay to follow ErbB–FAK localiza-
tion at the cell protrusion. Fig. 5 A reveals that both ErbB-2
and FAK are recruited into newly formed lamellipodia near
the leading edge of wounded cells during cell migration to the
acellular area (Fig. 5 A, 30 min). Typical ventral focal con-
tacts that were stained for FAK became detectable 6 h after
wound healing and become more pronounced after 24 h (Fig.
5 A, 24 h).
We then examined the subcellular localization of ErbB-2
and FAK by confocal microscopy. FAK
 / -2/3 cells exhibited
strong labeling of ErbB-2 that was homogeneously distributed
at the cell membrane. In contrast, FAK labeling was localized
to cell extensions at ventral focal contact sites in FAK
 /  con-
trol cells, whereas FAK
 / -2/3 cells exhibited multiple protru-
sions at the cell periphery, where FAK and ErbB-2 colocalized
(Fig. 5 B). This colocalization was also seen using specific an-
tibodies against the FAK phosphosites Tyr-397, -861, and -925
(Fig. 5 C). Because ErbB receptors physically interact with
FAK (Sieg et al., 2000; Vartanian et al., 2000), we examined
whether ErbB-2 and FAK colocalize to the cell membrane pro-
trusion as separate proteins or as a complex. Immunoprecipita-
tion studies on isolated plasma membranes from nonstimulated
and stimulated FAK
 / -2/3 cells revealed that ErbB-2 and
FAK were present on the cell membrane, at least in part, as a
preformed complex (Fig. S3, available at http://www.jcb.org/
cgi/content/full/jcb.200504124/DC1).
Figure 5. ErbB-2 colocalizes with FAK at focal adhesions in motile cells. (A) ErbB-2 and FAK colocalize in motile FAK
 / -2/3 cells. Confluent cells were
scratch wounded and allowed to heal for the indicated time points before fixation. Cells were then coimmunostained with anti–ErbB-2 and anti-FAK anti-
bodies followed by appropriate secondary antibodies as described in Materials and methods. Note that both ErbB-2 and FAK are recruited into newly
formed lamellipodia near the leading edge of the wounded cells during cell migration to the acellular area (30 min). Typical ventral focal contacts that
were stained for FAK become detectable 6 h after wound healing and become more pronounced after 24 h. Arrowheads indicate the newly formed pro-
trusions. Stars indicate the folded cell layer at the wounded area. Bar, 30  m. (B) Colocalization of ErbB-2 and FAK at the cell protrusion. Cells were
fixed, permeabilized, and double immunostained with anti–ErbB-2 and anti-FAK antibodies followed by appropriate secondary antibodies conjugated
either to aminomethylcoumarin (AMCA) or Texas red to detect ErbB-2 and FAK, respectively. The figure shows that FAK
 /  control cells were negatively
stained for both ErbB-2 and FAK, whereas FAK
 / -2/3 cells were strongly labeled for ErbB-2 receptors, which were homogeneously distributed around the
cell periphery. In contrast, FAK
 /  control cells exhibit strong labeling of FAK, which was localized to cell extensions and ventral focal contact sites within
the cells, whereas FAK
 / -2/3 cells exhibit strong labeling of FAK at cell protrusions, which colocalize partially with ErbB-2 receptors as revealed by dual-
color merged confocal images. (C) Tyrosine-phosphorylated FAK colocalized with ErbB-2. FAK
 /  control cells and FAK
 / -2/3 were grown in complete
medium, fixed, and immunostained with ErbB-2 in combination with either FAK Tyr-397, -861, or -925 antibodies. Confocal microscopy reveals partial
colocalization of phospho-FAK with ErbB-2 receptor at the cell protrusions (arrows). In contrast, control cells that do not express any ErbB exhibit homo-
geneous distribution of phospho-FAK at the focal contacts. (B and C) Bars, 50  m. FAK IS ESSENTIAL FOR ERBB ONCOGENESIS • BENLIMAME ET AL. 511
Next, we confirmed the colocalization of FAK and ErbB-2
in FAK
 / -2/3 cells in which FAK was reconstituted by immu-
nofluorescence. FAK
 / -2/3–FAK cells exhibited many focal
adhesions that were labeled for both FAK and vinculin, which is
similar to FAK
 / -2/3 cells (Fig. 6 A). The restoration of FAK in
FAK
 / -2/3 cells induced the relocalization of ErbB-2 from the
straight parts of the cell membrane to fingerlike protrusions in a
similar pattern to that seen in FAK
 / -2/3 cells (Fig. 6 B).
To further examine the importance of FAK domains for
ErbB localization, we compared the localization of ErbB-2
with cell protrusion in FAK
 / -2/3 cells that were transiently
transfected with wild-type FAK, FAK NH2 terminus (NT), or
FAK COOH terminus (CT); both were fused to GFP. The ex-
pression and activation of these truncated forms of FAK after
30 min of stimulation with EGF or HRG was confirmed by
immunoprecipitation analysis (Fig. 6 C). CT-FAK showed
no clear changes in phosphorylation after stimulation with
HRG. Immunofluorescence labeling revealed the presence of
focal adhesions that colocalize with vinculin in cells express-
ing CT-FAK, but the NT-FAK–transfected cells developed
less focal adhesions, as detected by vinculin staining (Fig. 6 D).
Furthermore, ErbB-2 was homogeneously distributed at the
cell membrane in cells transfected with control or CT-FAK–
GFP-expressing plasmid (Fig. 6 E). In contrast, NT-FAK–
GFP-transfected cells exhibited a reduced staining of ErbB-2,
which was localized throughout the cytoplasm.
Together, these results indicate that ErbB-induced cell
migration involves interaction with FAK and relocalization and
accumulation of ErbB-2 at the cell protrusion.
ErbB-2–induced invasion by FAK 
colocalizes in human cancer cells
To confirm the relevance of the results in mouse embryonic fi-
broblasts to human cells, we examined the importance of FAK
for cell invasion in a panel of human breast cancer cells, in-
cluding SKBR3 and T47D cells that overexpress ErbB-2 con-
stitutively, and two metastatic variants of the breast carcinoma
cells MDA-231-M2 and MCF7-M4 that were selected in vivo
from parental cells overexpressing ErbB-2. Fig. 7 A shows the
ErbB-2 status in these cells, which were examined by Western
blot analysis, and Fig. 7 B shows the efficiency of siRNA to
down-regulate FAK. We next examined the impact of FAK
down-regulation on cell invasion by using the Boyden chamber
assay on matched control and FAK siRNA cells.
Figure 6. Restoration of FAK in FAK
 /  cells
rescued focal adhesions and ErbB-2 relocal-
ization to focal protrusions. (A) FAK
 /  cells
cooverexpressing ErbB-2 and -3 receptors
were stably transfected with wild-type FAK as
described in Materials and methods. Double
immunofluorescence labeling of FAK and vin-
culin, a marker for focal adhesion, demon-
strated that FAK
 / -2/3 cells in which FAK
was restored (right) exhibited many focal ad-
hesions that were labeled for both FAK and
vinculin, which is similar to normal FAK
 / -2/3
cells. (B) Double immunofluorescence of FAK
and ErbB-2 revealed that the restoration of
wild-type FAK in FAK
 / -2/3 cells induces the
relocalization of ErbB-2 receptors from the cell
membrane to fingerlike protrusions. This ErbB-2
pattern is similar to FAK
 / -2/3 cells in which
FAK and ErbB-2 receptors colocalized at cell
protrusions. Bar, 30  m. (C) Expression of
NH2 terminus (NT) and COOH terminus (CT)
FAK in FAK
 / -2/3. Cells expressing the NT
or CT were stimulated without (C) or with 20
ng/ml EGF (E) or 20 ng/ml HRG (H) for 30
min. Equal amounts of protein were immuno-
precipitated with anti–FAK-A17, which targets
at NT-FAK, or anti-FAK–C-20 which targets at
CT-FAK. Blots were probed with antiphospho-
tyrosine antibody. (D and E) Immunofluores-
cence analysis. FAK
 / -2/3 cells expressing
control, CT-FAK–GFP, or NT-FAK–GFP fusion
protein (see Materials and methods). After
transfection, the cells were incubated in com-
plete medium for 24 h and were fixed and
coimmunostained for FAK and vinculin (D) or
FAK and ErbB-2 receptor (E). Note that focal
adhesions were seen only when cells were
transfected with CT-FAK but not with NT-FAK
(D). In contrast, cells transfected with CT-FAK
exhibited a homogeneous distribution of ErbB-2
receptors at the cell membrane, whereas
transfection with NT-FAK exhibited a reduced
staining of ErbB-2 throughout the cytoplasm (E).
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As noted in Fig. 7 C, cells expressing siRNA have re-
duced invasive activity. The exposure of cells to PP2 but not
UO126 inhibitors mimics the inhibitory effect of cell invasion
that was observed with FAK siRNA. Equally important, an in
vivo study using the highly invasive MDA-231-M2 cells indi-
cated that the expression of FAK siRNA is stable in vivo, as
shown by immunohistochemistry on tumor tissues taken at the
time of killing (Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200504124/DC1), and drastically reduced the
invasive capacity of these cells when implanted into the mam-
mary fat pad. 50 d after tumor implantation, the number of lung
nodules was reduced by  90% compared with control cells ex-
pressing control bulk siRNA (Fig. 7 D).
To confirm the colocalization of ErbB and FAK in SKBR3,
T47D, MDA-231-M2, and MCF7-M4, the ErbB-2 receptor was
coimmunolabeled with antibodies against ErbB-2 and FAK. Fig. 8
shows that both ErbB-2 and FAK colocalize to cell protrusions in
all of these cells. Double labeling of ErbB-2 and FAK indicate that
cells with ErbB-2 overexpression exhibit a strong colocalization of
FAK with ErbB-2 at the cell lamellipodia. In all cases, confocal
microscopy indicates that ErbB and FAK localization is partial.
Discussion
Increasing evidence highlighted a key role for the regulation of cell
invasion by cooperation between a number of growth factor recep-
tors, including the ErbB tyrosine kinases, and integrin-dependent
pathways. This cooperation has been suggested to result from the
amplification of cell signal transduction pathways, including the
recruitment of FAK and its network of interactors. In this study, we
dissected the importance of FAK for ErbB-induced cell invasion
versus oncogenesis in the context of combinatorial receptor over-
expression, a situation that is common in invasive cancers.
FAK is indispensable for ErbB-induced 
oncogenic transformation
Our results provide evidence that ErbB-2/3 cooverexpression in
FAK-proficient cells, but not in FAK-deficient cells, induced an-
Figure 7. FAK regulates ErbB-induced cell invasion and metastasis formation that is induced by human breast cancer cells. (A) ErbB-2 expression status
examined by Western blot analysis of cell extracts from cells constitutively overexpressing ErbB-2 (SKBR-3 and T47D) and metastatic cell variants (MCF7-M4
and MDA-231-M2) that were isolated in vivo from MCF7 and MDA-231 cells engineered to overexpress ErbB-2. (B) Western blots on cells stably expressing
control (bulk) or FAK siRNA. Note that FAK-specific siRNA induced a marked decrease of FAK expression. GAPDH used as an internal control was unaffected.
(C) Inhibition of FAK by siRNA reduced cell invasion to a similar level as observed after Src inhibition but not MAPK inhibition. Cells expressing siRNA or
treated with PP2 or UO126 were cultured in the upper chamber, whereas HRG was used as a chemoattractant in the lower chamber. Each bar of the
graphs represents the mean   SD of invading cells from three independent experiments. (D) The metastatic MDA-231-M2 cells were implanted into the
mammary fat pad. Animals were sacrificed 50 d later, lungs were fixed in Bouin, and surface lung metastases were counted. Each bar represents the mean
of five mice   SEM (error bars). Image is of representative lungs from these experiments. FAK IS ESSENTIAL FOR ERBB ONCOGENESIS • BENLIMAME ET AL. 513
chorage-independent growth on soft agar as well as tumor forma-
tion in vivo. Consistently, the restoration of FAK can rescue the
inability of FAK
 / -2/3– as well as FAK
 / -2–overexpressing
cells to induce growth on soft agar and tumor formation in vivo. In
contrast, this rescue was not observed in FAK
 /  cells expressing
the kinase-deficient ErbB-3 receptor, which relies on heterodimer-
ization with other members of the ErbB family, particularly with
ErbB-2, for transmitting oncogenic signals (Pinkas-Kramarski et
al., 1996). An essential role of FAK for oncogenic transformation
induced by v-Src, Ras, 12-dimethylbenz(a)nthracene, or TPA has
been reported (Renshaw et al., 1999; McLean et al., 2000; Lim et
al., 2004). In contrast, FAK was found to be dispensable for
v-Src–induced oncogenic transformation in contrast to cell motil-
ity (Hauck et al., 2002; Hsia et al., 2003).
Cross talk between ErbB and FAK is multidirectional. The
strong tumorigenic and invasive potential of the ErbB-2/3 combi-
nation is consistent with the potent mitogenic signals emanating
from the ErbB-2/ErbB-3 heterodimer compared with monomeric
receptors (Alimandi et al., 1995; Pinkas-Kramarski et al., 1996).
For instance, ErbB-2 overexpression can lead to constitutive au-
tophosphorylation and activation of the kinase-deficient ErbB-3,
whereas activation of ErbB-3 by HRG can transphosphorylate
ErbB-2; this cooperation results in the amplification of cell sig-
naling (Riese et al., 1995; Pinkas-Kramarski et al., 1996).
ErbB-induced cell transformation has been linked to sev-
eral signaling molecules that were also recruited by FAK, in-
cluding the Ras-MAPKs and Src. Like ErbB, FAK activation
results in the activation of multiple signaling molecules, in-
cluding Src family kinases and the adaptor protein Grb2. We
demonstrate that ErbB activation induces FAK phosphoryla-
tion at several sites, including Tyr-397, -861 and -925. These
sites have been shown to be the major regulated phosphory-
lated sites after ErbB activation by EGF or HRG (Sieg et al.,
2000; Lu et al., 2001; Vadlamudi et al., 2002, 2003). In our
model, ErbB-2/3 activation by HRG increased FAK phosphor-
ylation, which contrasts with other studies in which ErbB re-
ceptor activation in cells overexpressing a single receptor was
shown to induce FAK dephosphorylation (Lu et al., 2001;
Vadlamudi et al., 2002), but is in agreement with others
(Brunton et al., 1997; Hauck et al., 2001; Golubovskaya et al.,
2002). Nevertheless, changes in FAK phosphorylation status
by ErbB does not correlate with the potency of ErbB to induce
tumor invasion, because we observed a similar pattern of FAK
phosphorylation in cells overexpressing ErbB-1 or -1/3 recep-
Figure 8. ErbB-2 colocalizes with FAK at focal
adhesions in invasive breast cancer cells.
Cells were fixed, permeabilized, and sub-
jected to confocal microscopy after double
immunostaining with anti–ErbB-2 and anti-FAK
antibodies followed by appropriate secondary
antibodies conjugated either to Cy2 or Texas
red (left) or conjugated to AMCA and Texas
red (middle) to detect ErbB-2 and FAK, respec-
tively. The panels show a strong labeling of
FAK, which was localized to cell extensions
and ventral focal contact sites within the cells.
For all cell lines, dual-color merged confocal
images reveal a partial colocalization of
ErbB-2 with FAK (arrows). Bars, 50  m.JCB • VOLUME 171 • NUMBER 3 • 2005 514
tors despite the fact that these cells are less invasive compared
with cells overexpressing ErbB-2/3. This would support the
idea that FAK contributes to ErbB-induced cell invasion pri-
marily via its downstream pathways. Using inhibitors for
MEK1 and Src, we demonstrate that FAK involves two distinct
primary signaling molecules: namely, MAPK/ERK for cell
transformation and Src for cell invasion. First, oncogenic trans-
formation by ErbB-2/3 in FAK-proficient and FAK-reconstituted
cells correlated with a rapid ERK-1/2 activation compared with
FAK-deficient cells, supporting the idea that FAK is an impor-
tant mediator for the potent MAPK activation reported previ-
ously for heterodimeric forms containing ErbB-2 (Olayioye et
al., 2000). Interestingly, the inhibition of MAPK prevented
ErbB–FAK-dependent oncogenic transformation both in ErbB-
2/3 FAK-proficient and FAK-reconstituted cells. This also de-
pended on FAK–Src interaction because Src inhibition can
prevent ErbB-induced oncogenesis, which is in agreement
with previous studies on FAK–Src–MAPK-dependent signaling
for v-Src–induced cell transformation or chemotaxis (Schlaepfer
et al., 1998; Westhoff et al., 2004). Moreover, a study by Ren-
shaw et al. (1999) reported that unlike nontransformed cells,
oncogene-transformed cells induced anchorage independency
via MAPK activation, which bypasses a requirement for cell
adhesion and growth factor stimuli. Whether such a scenario
can account for ErbB–FAK-dependent oncogenic transforma-
tion in our models will require further studies.
FAK is essential for ErbB-induced cell 
chemotaxis, tumorigenesis, and 
metastasis formation
It has been suggested that the relationship between ErbB receptor
overexpression and cancer invasiveness is the result of the ampli-
fication of cell signal transduction, which is primarily attributed
to interreceptor heterodimerization. FAK-deficient cells have de-
fects in cell migration compared with FAK-proficient cells (Ilic et
al., 1995). We demonstrate that the overexpression of ErbB-2/3
receptors failed to induce tumorigenesis, which is in contrast to
FAK-proficient cells. However, the restoration of FAK can res-
cue the capacity of ErbB-2/3 to induce tumor formation. The de-
lay of tumor growth that was induced by FAK
 / -2/3–FAK cells
may be explained by low levels of exogenous FAK in FAK
 / -2/3
compared with FAK
 /  cells or by other mechanisms that operate
in vivo (e.g., regulation of tumor angiogenesis or stromal–host
interactions; Yen et al., 2002; Alaoui-Jamali et al., 2003).
The incidence of lung metastases was drastically reduced
in ErbB-2/3 FAK-deficient cells compared with ErbB-2/3
FAK-proficient cells, but the restoration of FAK in FAK
 / 
cells rescued the invasive potential of ErbB in these cells both
in vitro and in vivo. Nevertheless, we noted that metastasis for-
mation in vivo was not completely abolished in nonreconsti-
tuted ErbB–FAK-deficient cells compared with FAK-profi-
cient cells. However, lung metastases in this model form after
the intravenous injection of cells, which represents a late stage
process of metastasis. Alternatively, ErbB-2/3 receptors may
be able to override the requirement for FAK in vivo via alterna-
tive mechanisms such as a possible compensatory role for
Pyk2, which binds to ErbB-1 and is overexpressed in FAK-
deficient cells (Ivankovic-Dikic et al., 2000). Interestingly, in
human invasive cancer cells expressing ErbB-2/3 receptors, the
inhibition of FAK efficiently prevented the formation of lung
metastases from distant primary tumors implanted into the
mammary fat pad.
Both activated ErbB-2/3 and FAK can associate with c-Src.
c-Src utilizes Tyr-397 of FAK to interact with FAK (Schaller
et al., 1994), although others have shown that Src itself can in-
duce FAK tyrosine phosphorylation independently of Tyr-397
(McLean et al., 2000). HRG was shown to up-regulate the Tyr-
215 of c-Src and to increases Src kinase activity, and increased
Src activity is associated with reduced cell–cell adhesion (Ha-
maguchi et al., 1993) and increased metastatic potential (Irby et
al., 1999). Furthermore, cooperation between Src and ErbB in
tumorigenesis and invasion has been previously reported (Maa et
al., 1995). Interestingly, FAK-related nonkinase expression in
v-Src–transformed NIH3T3 cells inhibited FAK phosphoryla-
tion at Tyr-861 and formation of lung metastases but did not
inhibit the growth of primary tumors (Hauck et al., 2002).
Because the inhibition of Src is found to prevent ErbB–
FAK colocalization to focal adhesions, one possibility is that Src
may regulate the focal adhesion turnover of podosome-associ-
ated Src substrates, as reported previously (Fincham and Frame,
1998; Carragher et al., 2002). Additional mechanisms may imply
a regulation of cell cytoskeleton reorganization via FAK signal-
ing because changes in several cytoskeleton proteins were noted
in ErbB-transformed cells (Alaoui-Jamali et al., 2003).
ErbB–FAK localizes specifically to cell 
protrusions in migratory cells 
The connection between ErbB and cell invasion can occur at mul-
tiple levels, including the regulation of focal adhesions. Focal ad-
hesions are primarily localized to the cell periphery, are highly
phosphorylated, contain proteins such as  v 3 integrin, vinculin,
and paxillin, and function primarily by providing anchors to the
extracellular matrix, thus allowing the contractile actomyosin sys-
tem to pull the cell body and trailing edge forward. As noted in
our results, migratory ErbB-2/3 cells display fingerlike protru-
sions at highly organized plasma membrane structures. Interest-
ingly, ErbB localization with vinculin, which is a marker for focal
adhesions, was dependent on activated FAK, as exogenous FAK
can restore ErbB localization to focal adhesion sites in FAK-defi-
cient cells. Confocal microscopy combined with immunoprecipi-
tation assay on purified cell membranes confirmed that ErbB and
FAK colocalize, in part, as a preformed complex, which is also
supported by the previously reported physical interaction between
ErbB and FAK (Sieg et al., 2000; Vartanian et al., 2000).
However, bidirectional receptor endocytosis/exocytosis
raises a question about the specificity of ErbB localization to focal
adhesions versus receptor recycling mechanisms. ErbB-2, unlike
ErbB-1, has a long half-life at the plasma membrane that is attrib-
uted to its capacity to overcome clathrin-mediated endocytosis
and proteolysis and/or increased recycling (Baulida et al., 1996;
Waterman et al., 1998). In a panel of human invasive cancers, we
confirmed that FAK regulates ErbB-induced cell invasion and
metastasis formation when cells were implanted into the mam-
mary fat pad. Of relevance to this study, ErbB-2 is found to be FAK IS ESSENTIAL FOR ERBB ONCOGENESIS • BENLIMAME ET AL. 515
preferentially associated with membrane protrusions in SKBR3
cells, where it becomes highly resistant to internalization (Hom-
melgaard et al., 2004). This seems to be independent of ErbB-2
association with (1) lipid rafts or the actin cytoskeleton (Mineo et
al., 1999); (2) caveolae, which represents a subset of rafts (Nagy et
al., 2002); or (3) the actin cytoskeleton (Feldner and Brandt,
2002). These observations support that ErbB–FAK colocalization
at cell protrusions is involved in cell migration. In summary, our
data provide evidence that the potent invasive property of
ErbB-2/3 receptors is mediated via FAK-dependent mechanisms.
Materials and methods
Reagents and cell lines
Mouse embryonic fibroblast (FAK
 /  or FAK
 / ) cells were provided by
D. Ilic (University of California, San Francisco, San Francisco, CA). SKBR-3,
T47D, MCF-7, and MDA-231 cells were obtained from the American Type
Culture Collection. The metastatic variants MDA-231-M2 and MCF7-M4
were established from metastatic lung nodules induced in vivo by parental
cells that were engineered to overexpress ErbB-2 and implanted into the
mammary fat pad of Scid mice. The following antibodies were used: mono-
clonal anti–ErbB-2 (Ab-3; clone 3B5) and polyclonal anti–ErbB-2 (Ab-1; On-
cogene Research Products); polyclonal anti–ErbB-3 (clone C-17), polyclonal
anti-FAK (A-17; C-20), and antiphospho–FAK-Y925 (Santa Cruz Biotechnol-
ogy, Inc.); antiphospho–FAK-Y397 and antiphospho–FAK-Y861 (Biosource
International); antiphosphotyrosine antibody (4G10) and anti–ERK-2 (clone
B3B9; Upstate Biotechnology); antiphospho-MAPK (New England Biolabs,
Inc.); monoclonal antivinculin (clone hVIN-1; Sigma-Aldrich); and anti-
GAPDH (Cedarlane). EGF was obtained from Sigma-Aldrich, HRG was pur-
chased from Neomarkers, and PP2 and UO126 were obtained from Alexis
Biochemicals. The dominant-negative mutants for MEK1 and Src were pro-
vided by S. Meloche (Montreal University, Montreal, Canada) and D. Shal-
loway (Cornell University, Ithaca, NY), respectively.
Cell culture
FAK
 /  or FAK
 /  cells were cultured in DME (Life Technologies) supple-
mented with 10% FBS, 1 mM sodium pyruvate, 1% (vol/vol) nonessential
amino acids, 100  M 2-mercaptoethanol, and penicillin/streptomycin.
Human cancer cells were maintained in Roswell Park Memorial Institute
1640 medium supplemented with 10% FBS and penicillin/streptomycin.
Stable overexpression of ErbB receptors in FAK
 /  and FAK
 /  cells
ErbB receptors were expressed in a polyclonal cell population as described
previously (Yen et al., 2002).
Construction of plasmids and transfection
The plasmid encoding mouse FAK was described previously (Sieg et al.,
2000). The cDNA encoding FAK residues 231–1,538 and residues
2,281–3,378 were amplified by PCR from a human osteosarcoma cDNA
library. Both fragments were subcloned into the BglII–ApaI sites of the
pEGFP-N2 expression vector (CLONTECH Laboratories, Inc.). For both sta-
ble and transient transfections, cells at 50% confluence were transfected
with 2  g plasmid DNA for 18 h using LipofectAMINE (Invitrogen). For
transient expression, cells were collected 24–48 h after incubation in com-
plete medium. For stable expression, cells were transfected for 18 h and
were cultured in completed medium containing 500  g/ml hygromycin
for 14 d. Clones with a stable expression of FAK were isolated.
Anchorage-independent cell growth
5,000 cells were suspended in 0.3% SeaPlaque agarose (Mandel Sci-
entific Company) diluted in complete medium and were poured on a
0.7% preformed layer of agarose. Cells were incubated at 37 C and
reefed every 3 d with fresh DME. 4 wk later, cell foci that were  20  m
in diameter were counted.
Western blot and immunoprecipitation assays
Western blot and immunoprecipitation assays were described previously
(Yen et al., 2002). When indicated, cells were either pretreated with PP2
at 1–10  M or UO126 at 10  M or were transiently transfected with
dominant mutants for Src and MEK1 using Fugene reagent (Roche Diag-
nostics) following similar experimental conditions for FAK as described in
Construction of plasmids and transfection.
Generation of cells expressing stable FAK siRNA
A specific 19-nt sequence spanning positions 466–484 of FAK human
gene (GenBank/EMBL/DDBJ accession no. L10616) was cloned as in-
verted repeats into pSuper-retro puromycin vector according to the manu-
facturer’s instructions (Oligoengine). Control retroviral vector pRetro-Super
puromycin alone or expressing FAK siRNA was transfected into Phoenix
cells using Genejuice (Novagene). After 48 h after transfection, the super-
natant of Phoenix cells was filtered through a 0.45- m filter and was used
to infect target cell lines twice, 24 h apart, in the presence of 8  g/ml po-
lybrene. 48 h after infection, polyclonal populations were selected for resis-
tance to 1  g/ml puromycin for 2 wk to generate stable siRNA-expressing
cells and matched (bulk) controls.
Scratch motility assay
Cells grown on coverslips were wounded by cell scraping with a micropi-
pette tip. Cultures were washed and incubated in complete medium. Cells
were incubated at 37 C for different periods of time to allow migration to-
ward the gap and were then fixed, permeabilized, and immunostained
for both ErbB-2 and FAK.
Invasion assay
Cell invasion experiments were performed with 8- m porous chambers
coated with matrigel (Becton Dickinson) according to the manufacturer’s rec-
ommendations. 20 ng/ml EGF or HRG were used as chemoatractants in the
lower compartment. Cells were allowed to invade through the matrigel
membrane for 48 h. The invasive cells underneath were fixed and stained.
Immunofluorescence labeling
FAK
 /  and FAK
 /  cells overexpressing ErbB receptors were processed
for immunofluorescence as previously described (Yen et al., 2002). When
indicated, cells were incubated for 24 h in serum-free medium and were
pretreated with 100 nM PP2 before adding 20 ng/ml EGF or HRG for 15
min. After labeling, the cells were viewed with a fluorescent microscope
(Axiophot; Carl Zeiss MicroImaging, Inc.) equipped with a 63  plan
Apochromat objective and selective filters. Images were acquired from a
cooled CCD camera (Retiga 1300; Q Imaging) and displayed on a high
resolution monitor. Images were analyzed by the Northen Eclipse Image
analysis system (Carl Zeiss MicroImaging, Inc.). Confocal analyses were
performed with an inverted confocal microscope (McGill University; model
LSM 510; Carl Zeiss MicroImaging, Inc.).
In vivo tumorigenic and invasion studies
In vivo studies were approved by the McGill Animal Care Committee
(protocol 4101) and were conducted in accordance with institutional
and Canadian federal guidelines. For primary tumors, one million cells
were injected subcutaneously into the flank of Scid mice (FAK
 /  and
FAK
 /  cells) or into the mammary fat pad (MDA-231-M2). Tumor vol-
umes were measured every second or third day as described previously
(Alaoui-Jamali et al., 2003). For tumor invasion, one million cells per 100
 l were injected intravenously (FAK
 /  and FAK
 /  cells) or into the mam-
mary fat pad (human breast cancer cell line MDA-231-M2). Animals
were killed 4–8 wk after cell inoculation. The lungs were fixed in 10%
Bouin’s fixative, and lung surface metastases were counted.
Online supplemental material
Fig. S1 shows the impact of ErbB receptors that are expressed as single or
paired combinations on the metastatic and chemotactic properties of mouse
embryonic fibroblast (FAK
 / ) cells described in this study. Fig. S2 shows rep-
resentative images of colony formation in agar and cell chemotaxis through
the matrigel of the Boyden chamber. Fig. S3 shows that ErbB-2 and FAK coim-
munoprecipitate from purified plasma membranes. Fig. S4 shows that FAK
siRNA is stable in MDA-231-M2 tumors growing into the mammary fat pad,
as revealed by immunohistochemistry analysis. Online supplemental material
is available at http://www.jcb.org/cgi/content/full/jcb.200504124/DC1.
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